Menopause Treatment: A Doctor's Guide for 2026

What "menopause treatment" actually refers to

Menopause is not a disease. It is the point 12 months after a woman's final menstrual period, and "menopause treatment" is shorthand for managing the symptoms and long-term physiologic changes that follow the drop in ovarian estrogen and progesterone. The main treatment categories are: systemic hormone therapy (estradiol, with or without a progestogen), local vaginal estrogen or DHEA (prasterone) for genitourinary symptoms, non-hormonal prescription medications (fezolinetant, certain SSRIs/SNRIs, gabapentin, oxybutynin), and lifestyle or behavioral approaches. These are not interchangeable, each targets a different symptom cluster and carries a different risk profile, and the source literature does not support treating them as equivalent options for every woman.

The core, quotable answer: for a healthy woman under age 60 or within 10 years of her final period, with no personal history of hormone-receptor-positive breast cancer, active clotting disease, or unexplained vaginal bleeding, systemic hormone therapy has the strongest evidence base for relieving moderate-to-severe hot flashes and preventing accelerated bone loss. Outside that timing window, or when those risk factors are present, the benefit-risk balance shifts and non-hormonal options (fezolinetant for vasomotor symptoms, local vaginal estrogen or prasterone for genitourinary symptoms) generally become the first choice, with hormone therapy considered case by case in coordination with the treating specialist.

The three stages, briefly

Perimenopause is the period of fluctuating hormone production before periods stop; cycles become irregular and vasomotor symptoms, sleep disruption, and mood changes often begin here.

Menopause is the single retrospective date, 12 months after the last period, not a stage you are "in."

Postmenopause covers every year afterward, when estrogen and progesterone remain chronically low and cardiovascular risk, bone density, and vaginal tissue health shift over the long term.

Menopause before age 40, premature ovarian insufficiency (POI), is a distinct clinical situation with different treatment priorities and is discussed separately below. Background on POI is available from the NCBI Bookshelf clinical overview.

Diagnosis: what testing actually adds

Most women do not need laboratory testing. Menopause is a clinical diagnosis based on age, symptom pattern, and 12 months without a period.

Follicle-stimulating hormone (FSH) testing can support the diagnosis in ambiguous cases, most relevantly in women under 45, or in women using hormonal contraception that masks bleeding patterns. A single FSH value is unreliable during perimenopause because levels fluctuate considerably from week to week; guidance from the Endocrine Society notes this variability directly, and most clinicians who use FSH in this setting repeat it on a separate occasion rather than acting on one result.

Thyroid dysfunction, elevated prolactin, and pregnancy can all mimic perimenopausal symptoms. A TSH, prolactin level, and urine hCG are reasonable first steps before attributing irregular cycles in a woman under 45 to ovarian decline.

Hormone therapy: what it does and where its evidence is strongest

Systemic hormone therapy is the most extensively studied treatment for moderate-to-severe vasomotor symptoms and for the accelerated bone loss that follows estrogen withdrawal.

Estrogen-only therapy is used after hysterectomy, since there is no endometrium to protect. Options include oral estradiol, transdermal patches, gels, and sprays. Transdermal delivery bypasses first-pass liver metabolism, and observational and mechanistic data suggest a more favorable effect on triglycerides and clotting factors compared with oral estrogen, though this has not been confirmed for cardiovascular hard endpoints in large randomized trials.

Combined estrogen-progestogen therapy is required when the uterus is intact, because the progestogen protects the endometrium from estrogen-driven overgrowth. Options include oral micronized progesterone, norethindrone acetate, and the levonorgestrel-releasing IUD, which delivers progestogen locally rather than systemically.

The Menopause Society's periodically updated position statement on hormone therapy describes a favorable benefit-risk ratio for treating bothersome vasomotor symptoms and preventing bone loss in women under 60 or within 10 years of menopause onset who have no contraindications. Readers who want the exact current wording should consult the live statement rather than a quoted excerpt, since these statements are revised over time.

The timing hypothesis, and why it matters more than the headline WHI numbers

The Women's Health Initiative (WHI) enrolled women aged 50 to 79 (mean age around 63) and its initial results, reported in the early 2000s, showed increased breast cancer and cardiovascular events with combined hormone therapy, which led to a sharp global decline in prescribing. Later age-stratified re-analysis, often called the "timing hypothesis", found that women who started hormone therapy close to menopause (within about 10 years, or before age 60) had more favorable cardiovascular outcomes than women who started it two decades or more after menopause. This reanalysis is influential in current guidance, but it is a secondary analysis of trial subgroups rather than a dedicated trial of younger women, and exact effect sizes from that reanalysis should be checked against the primary WHI publications before being quoted precisely.

Vaginal (local) estrogen and genitourinary syndrome of menopause

Genitourinary syndrome of menopause (GSM) includes vaginal dryness, painful intercourse, urinary urgency, and recurrent urinary tract infections. Low-dose vaginal estrogen, cream, ring, or tablet, delivers estrogen locally with minimal systemic absorption and is considered first-line for GSM by current guidance, including recently updated clinical reviews on this topic (Updates in care for patients with genitourinary syndrome of menopause, 2026). Vaginal estrogen has a different, generally more favorable systemic risk profile than systemic hormone therapy, and many oncologists will discuss its use even in women with a history of hormone-sensitive cancer, this remains an individualized decision made with the treating oncologist, not a blanket recommendation.

Non-hormonal prescription options

Fezolinetant (Veozah), a neurokinin-3 receptor antagonist, received FDA approval in 2023 specifically for moderate-to-severe vasomotor symptoms of menopause. It works through the hypothalamic KNDy-neuron pathway that regulates the body's thermoregulatory "thermostat," rather than by replacing estrogen, which is why it is an option for women who cannot or do not want to take hormones. Clinical trials reported clinically meaningful reductions in hot flash frequency compared with placebo; exact percentage figures vary by trial and should be verified against the primary trial publications before being cited to a specific patient. Liver enzyme monitoring is required before starting and during the first months of treatment.

Paroxetine mesylate (Brisdelle) 7.5 mg is the only SSRI FDA-approved specifically for vasomotor symptoms of menopause, at a lower dose than antidepressant use.

Venlafaxine, desvenlafaxine, and escitalopram are used off-label for hot flashes, with the largest evidence base for venlafaxine, including in breast cancer survivors who cannot use estrogen. These are FDA-approved as antidepressants, not for menopausal symptoms, so this is off-label prescribing.

Gabapentin, dosed in divided doses, has trial evidence for reducing hot flash frequency and may be particularly useful when sleep disruption or neuropathic pain coexist. This is also off-label use.

Oxybutynin, an anticholinergic typically used for overactive bladder, has trial evidence for hot flash reduction, again off-label; anticholinergic side effects (dry mouth, constipation, and caution around cognitive effects in older women) are relevant here.

Ospemifene (Osphena), a selective estrogen receptor modulator, is FDA-approved specifically for moderate-to-severe painful intercourse related to menopause, and is the main oral non-estrogen prescription option for that symptom.

Prasterone (Intrarosa), a vaginal DHEA insert, converts locally to estrogen and testosterone within vaginal tissue and is FDA-approved for painful intercourse due to vulvovaginal atrophy, with trial data showing improvement in dryness and dyspareunia without a detectable rise in serum estrogen.

Where this guide cited specific percentage reductions or trial sample sizes drawn from the prior draft's numbered references, those figures could not be verified against a confirmed, matching source and have been removed or generalized rather than repeated. Anyone relying on an exact effect size for a specific medication should check the primary trial publication before using that number in patient counseling.

Bone health: prevention and treatment thresholds

Estrogen withdrawal accelerates bone remodeling, and postmenopausal women lose bone mineral density at an increased rate in the years immediately following menopause; the precise annual percentage varies across studies and should not be quoted as a fixed figure without checking the source study's population and timeframe.

The USPSTF recommends bone density screening with DEXA for women 65 and older, and for younger postmenopausal women whose 10-year fracture risk is elevated enough to match that of a 65-year-old woman with no additional risk factors, based on a validated fracture-risk tool. A T-score at or below -2.5 at the spine, hip, or femoral neck meets the WHO definition of osteoporosis and generally triggers a conversation about pharmacologic treatment (bisphosphonates, denosumab, raloxifene, or hormone therapy) regardless of symptoms.

Hormone therapy preserves bone density and, in the WHI, reduced fracture rates compared with placebo; readers who want the exact reduction percentages for hip versus total fracture should consult the primary WHI publication rather than a secondhand figure, since precise numbers differ depending on which WHI report and which subgroup is referenced.

Cardiovascular risk: the timing window is the whole story

Heart disease is the leading cause of death in postmenopausal women, and estrogen has favorable effects on endothelial function, LDL cholesterol, and insulin sensitivity during the perimenopausal window. The clinically important finding from the WHI age-stratified reanalysis is directional and consistent across several supporting studies: women who start hormone therapy earlier relative to menopause (roughly within 10 years, or before age 60) tend to have more favorable cardiovascular outcomes than women who start it much later. A specific relative-risk number from a single reanalysis subgroup should not be generalized to women starting hormone therapy at older ages, the same studies that show benefit in the early window generally show no benefit, or possible harm, when therapy starts well after age 60 to 70.

Oral estrogen raises triglycerides and inflammatory markers through first-pass liver metabolism. Transdermal estradiol avoids this first-pass effect and is often preferred in women with elevated triglycerides or a history of venous thromboembolism, though it has not been directly tested against oral estrogen in a large randomized trial with cardiovascular events as the primary endpoint.

Breast cancer risk: putting it in proportion without inventing precision

This is the most common reason women decline hormone therapy, so it deserves a careful, honest answer rather than a single memorized number.

What is established: the WHI found a small absolute increase in breast cancer diagnoses with combined (estrogen plus synthetic progestogen) hormone therapy after several years of use. The increase is small in absolute terms, commonly described as low single-digit additional cases per 10,000 women per year, though the exact figure depends on which WHI follow-up analysis is cited, and a precise number should be checked against the primary publication before it is repeated to a patient as a fixed statistic.

What is also established: estrogen-only hormone therapy (used after hysterectomy) was associated with fewer breast cancer diagnoses than placebo in the WHI estrogen-only arm, not more. This is one of the more counterintuitive and clinically important findings in the whole hormone therapy literature, and it is a major reason estrogen-only therapy is treated differently from combined therapy in risk counseling.

What is plausible but needs its own verification: several observational cohort studies, including large European cohorts, have suggested that micronized progesterone may carry a lower breast cancer signal than synthetic progestogens such as medroxyprogesterone acetate. This is cohort-level, not trial-level, evidence and should be described to patients as an area of ongoing study rather than a settled fact.

What changes the calculation entirely: a personal history of hormone-receptor-positive breast cancer, a known BRCA1/2 pathogenic variant, or a substantially elevated calculated breast cancer risk moves a woman out of standard first-line hormone therapy decision-making and into individualized, oncology-coordinated care. For women with BRCA1/2 mutations who have had risk-reducing surgery, hormone therapy decisions have their own dedicated literature and should be made with a specialist familiar with that population (hormone therapy after risk-reducing salpingo-oophorectomy in BRCA1/2 carriers, 2026).

Comparing the main options

Who should generally avoid systemic hormone therapy

Recognized contraindications to systemic estrogen include:

• Active, recent, or suspected hormone-receptor-positive breast cancer
• Active or recent venous thromboembolism (DVT or pulmonary embolism)
• Active or recent arterial thromboembolic disease (stroke, myocardial infarction)
• Unexplained vaginal bleeding
• Active liver disease
• Known or suspected pregnancy

Situations requiring extra caution and often a preference for transdermal over oral estrogen include significantly elevated triglycerides, uncontrolled hypertension, active gallbladder disease, and migraine with aura. These are the kinds of decisions that belong in a direct conversation with a prescriber familiar with the individual's full history, not a checklist applied in isolation.

When to seek urgent care rather than wait for a scheduled visit: sudden chest pain, one-sided weakness or vision change, leg swelling with pain suggestive of a blood clot, or new unexplained vaginal bleeding while on or off hormone therapy all warrant same-day evaluation rather than being managed at a routine follow-up.

A decision framework for choosing a starting point

This resource should not replace a personalized clinical assessment. Instead, it highlights the key factors that meaningfully affect recommendations, allowing readers to identify their circumstances before meeting with their clinician.

Step 1, What is the dominant symptom?

• Hot flashes / night sweats / sleep disruption → go to Step 2.
• Vaginal dryness, painful intercourse, recurrent UTIs, with few or no hot flashes → local vaginal estrogen, prasterone, or ospemifene are usually the starting point regardless of the timing window below, since systemic absorption is minimal.
• Bone loss found on screening with few symptoms → go directly to the bone-health treatment threshold discussion; hormone therapy is one option among several, decided on fracture risk, not symptoms alone.

Step 2, Does the timing window apply? Under 60 years old, or within 10 years of the final menstrual period, and otherwise healthy → systemic hormone therapy has the strongest evidence base and is a reasonable first-line discussion. Starting more than 10 years after menopause, or after age 60, for the first time → the cardiovascular timing-hypothesis evidence no longer favors hormone therapy the same way; non-hormonal prescription options are usually tried first, with hormone therapy reserved for individualized discussion.

Step 3, Does a contraindication or red-flag history apply? Any item on the contraindication list above, a personal history of hormone-receptor-positive breast cancer, a BRCA1/2 pathogenic variant, or active/recent clotting disease → systemic hormone therapy is generally set aside. Move to fezolinetant, an off-label SSRI/SNRI or gabapentin, and coordinate with the relevant specialist (oncology, hematology) before any hormone-related decision, including about vaginal estrogen.

Step 4, Uterus intact or absent? Uterus present → estrogen must be paired with a progestogen or delivered via a levonorgestrel IUD to protect the endometrium; unscheduled bleeding on this regimen needs evaluation, not just reassurance. Uterus absent (prior hysterectomy) → estrogen-only therapy is an option, with a different and more favorable breast cancer signal in the trial data described above.

Step 5, Route selection when hormone therapy is appropriate Elevated triglycerides, prior VTE, migraine with aura, or a preference to avoid first-pass liver effects → transdermal (patch, gel, spray) is generally preferred over oral estrogen. No such factors → oral or transdermal are both reasonable; the choice is largely preference and cost.

Step 6, If hormone therapy is not appropriate or not desired Fezolinetant is the only non-hormonal medication FDA-approved specifically for vasomotor symptoms and is a reasonable first non-hormonal choice once liver function is confirmed to be normal at baseline. Venlafaxine, gabapentin, or oxybutynin are reasonable off-label alternatives, chosen based on coexisting conditions (sleep disruption favors gabapentin; overactive bladder symptoms favor oxybutynin).

Step 7, When to escalate beyond a primary care or general gynecology visit Menopause before age 40, contraindications to standard therapies, breast cancer survivorship, symptoms uncontrolled after two reasonable treatment trials, or significant bone loss needing fracture-risk-specific management are all reasons to involve an endocrinologist, gynecologist with menopause expertise, or oncologist rather than continuing to adjust doses in isolation.

Monitoring once treatment starts

Before prescribing: blood pressure, a pelvic exam and up-to-date cervical screening if due, a recent mammogram per age-based screening guidelines, and an explicit chart note of any contraindications. A DEXA scan is added when age or risk factors meet the screening threshold described above.

Around three months in: reassessment of symptom control, blood pressure recheck, and evaluation of side effects such as breast tenderness, bloating, or irregular bleeding, which often prompt a dose or route adjustment rather than discontinuation. Anyone on fezolinetant needs liver function testing at this stage per its labeling.

Annually: repeat blood pressure and relevant labs, mammogram per age-based guidelines, and evaluation of any unscheduled bleeding with pelvic ultrasound. Age past 60 while doing well on therapy started earlier is not, by itself, a reason to stop, current guidance frames this as an individualized conversation about dose and route rather than a mandated cutoff, but that conversation should happen, not be skipped by default.

Lifestyle and behavioral approaches

Lifestyle changes rarely eliminate moderate-to-severe symptoms on their own, but they carry essentially no risk and have supporting trial evidence at the margins.

Aerobic exercise has been associated with reduced hot flash severity scores in trial data, though effects on hot flash frequency specifically have been less consistent across studies. Resistance training two to three times a week helps preserve muscle mass and bone density, both of which decline faster after menopause.

Structured cognitive behavioral therapy (CBT) programs have reduced how distressing hot flashes feel, the "bother score", even when they do not reduce how often hot flashes occur. This distinction matters: CBT is not a substitute for a treatment that reduces frequency in someone whose hot flashes are frequent and severe, but it is a legitimate option for someone whose main problem is the distress response.

Reducing alcohol and evening caffeine intake is a reasonable, low-risk suggestion based on observational associations with vasomotor symptom triggers, rather than trial evidence of a specific effect size.

Special populations

Premature ovarian insufficiency (POI): women who reach menopause before 40 face a longer duration of estrogen deficiency than women with natural-age menopause, and guidance generally supports hormone therapy at least until the average age of natural menopause to protect bone and cardiovascular health, regardless of symptom severity. The exact wording and duration recommendations vary by guideline body and should be checked against the current version before being treated as fixed policy.

Breast cancer survivors: systemic hormone therapy is generally avoided with a history of hormone-receptor-positive breast cancer. Low-dose vaginal estrogen and prasterone are discussed individually with oncology. Fezolinetant, venlafaxine, and gabapentin are reasonable first-line systemic options for vasomotor symptoms in this group.

After hysterectomy: estrogen-only therapy avoids progestogen-related side effects and, in the WHI estrogen-only arm, was not associated with increased breast cancer risk.

Starting hormone therapy for the first time after 60 to 65: this requires individualized assessment rather than a default yes. Cardiovascular risk is higher, the timing window described above has closed, and non-hormonal options are usually tried first for vasomotor symptoms. Vaginal estrogen for genitourinary symptoms remains appropriate at any age, since its systemic exposure is minimal.

What is established, what is plausible, and what is not established

Established: hormone therapy is the most effective treatment for moderate-to-severe vasomotor symptoms and protects bone density; the benefit-risk ratio is more favorable when started close to menopause; estrogen-only therapy and combined therapy carry different breast cancer signals; vaginal estrogen has minimal systemic absorption; fezolinetant is FDA-approved specifically for vasomotor symptoms and works through a non-estrogen pathway.

Plausible but not fully settled: the exact magnitude of benefit from micronized progesterone versus synthetic progestogens on breast cancer risk; the precise degree of cardiovascular benefit from very early initiation; the comparative long-term safety of transdermal versus oral estrogen for hard cardiovascular endpoints, which has not been directly tested in a dedicated large trial.

Not established: a universal upper age limit for continuing hormone therapy in a woman who started before 60 and is doing well; a fixed, generalizable percentage reduction in hot flash frequency that applies identically to every non-hormonal medication across all patient populations, these figures vary meaningfully by trial and should be checked before being quoted as a single number.

Frequently asked questions

References and further reading

• Menopause Society clinical practice guidance, Endocrine Society clinical guideline hub, background on diagnosis and testing limitations
• USPSTF osteoporosis screening recommendation, screening thresholds and populations
• NCBI Bookshelf overview of premature ovarian insufficiency, background on POI diagnosis and management priorities
• Updates in care for patients with genitourinary syndrome of menopause (2026), current clinical review supporting the GSM treatment discussion above
• Hormone replacement therapy in BRCA1/2 mutation carriers after risk-reducing salpingo-oophorectomy: a practitioner toolkit (2026), relevant to hormone therapy decisions in BRCA1/2 carriers specifically

Several numeric claims and trial citations present in earlier drafts of this article (specific percentage effect sizes, exact WHI subgroup figures, and a directly quoted position-statement passage) could not be matched to a verifiable, correctly identified source and have been generalized, qualified, or removed rather than repeated. Anyone updating this page with precise statistics should confirm each figure against the primary trial or guideline publication before publishing it as a stated fact.